Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Open accessAbstract
The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1 on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is a promising therapeutic target.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CK1α is required for hematopoietic stem cell survival, and heterozygous deletion of its gene in del(5q) MDS creates a therapeutic window to eliminate the malignant stem cell clone.
“CK1α is essential for the survival of hematopoietic stem cells, and heterozygous deletion of its gene in del(5q) myelodysplastic syndrome provides a therapeutic window for eliminating the malignant stem cell clone (10).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [10]
The Results section, “Csnk1a1 is required for adult murine hematopoiesis” (page unavailable), reports that complete Csnk1a1 deletion sharply reduced hematopoietic stem cells, indicating a requirement for their survival. The Discussion and the Results section on CK1 inhibition describe a therapeutic window for targeting del(5q) haploinsufficient cells, but the experiments show selective loss of viability in cultured cells, not elimination of the malignant stem cell clone. (LLM, conf=0.86)
Experimental — accuracy not yet measuredLenalidomide-induced degradation of the remaining CK1α mimics biallelic loss of CSNK1A1, which triggers p53 activation, enhances apoptosis and leads to clonal arrest of the 5q-deleted population, ultimately driving disease regression.
“However, lenalidomide-induced degradation of the remaining cK1α mimics biallelic loss of CSNK1A1 which triggers p53 activation, enhances apoptosis and leads to clonal arrest of the 5q-deleted population which ultimately drives disease regression (wei et al. 2009;Schneider et al. 2014;Krönke et al. 2015).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Schneider et al. 2014
The Results section on adult murine hematopoiesis reports that complete Csnk1a1 deletion activated p53 and increased apoptosis; the CK1-inhibition Results section reports selective depletion of haploinsufficient cells with D4476. The paper does not establish that lenalidomide degrades CK1α or that this mechanism causes clonal arrest and disease regression. The indexed passages provide no page numbers. (LLM, conf=0.89)
Experimental — accuracy not yet measuredMutations in TP53 lead to resistance to lenalidomide in patients with MDS.
“Accordingly, mutations in TP53 lead to resistance to lenalidomide in patients with MDS97,98 (FIG. 3).”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
Resistance to lenalidomide and disease progression are associated with an increased frequency of TP53 mutations in patients with del(5q) MDS.
“Consistent with these experimental findings, resistance to lenalidomide and disease progression are associated with an increased frequency of TP53 mutations in patients with del(5q) MDS98,161,162.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · see citing works
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763 · see citing works
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257 · see citing works
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,223 · see citing works
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 925 · see citing works
Self-citationThe Wnt/β-catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Wang, Y., Krivtsov, A., Sinha, A., North, T., Goessling, W., Feng, Z.-H., Zon, L., & Armstrong, S. (2010) · Science · doi:10.1126/science.1186624 · Cited by 812 · see citing works
Haase, D. T., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kündgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 792 · see citing works
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 736 · see citing works
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F. C., Argiropoulos, B., Sung, S., Morin, R. D., Muranyi, A., Hirst, M., Hogge, D. E., Marra, M. A., Wells, R. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 655 · see citing works
A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone
Zhu, H., Guo, Z., Jiang, X., Li, H., Wang, X.-Y., Yao, H., Zhang, Y., & Mao, N. (2010) · Nature Protocols · doi:10.1038/nprot.2009.238 · Cited by 588 · see citing works
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Shirai, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2011) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 582 · see citing works
Casein kinase 1 γ couples Wnt receptor activation to cytoplasmic signal transduction
Davidson, G. R., Wu, W., Shen, J., Bilić, J., Fenger, U., Stannek, P., Glinka, A., & Niehrs, C. (2005) · Nature · doi:10.1038/nature04170 · Cited by 581 · see citing works
A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency
Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J. B., McArthur, G. A., Westmoreland, S. V., Chambon, P., Scadden, D. T., & Purton, L. E. (2007) · Cell · doi:10.1016/j.cell.2007.05.014 · Cited by 535 · see citing works
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Kode, A., Manavalan, J. S., Mosialou, I., Bhagat, G., Rathinam, C. V., Luo, N., Khiabanian, H., Lee, A., Murty, V. V. V. S., Friedman, R. A., et al. (2014) · Nature · doi:10.1038/nature12883 · Cited by 530 · see citing works
Kirstetter, P., Anderson, K., Porse, B., Jacobsen, S., & Nerlov, C. (2006) · Nature Immunology · doi:10.1038/ni1381 · Cited by 504 · see citing works
Casein kinase I transduces Wnt signals
Peters, J. M., McKay, R. M., McKay, J. P., & Graff, J. M. (1999) · Nature · doi:10.1038/43830 · Cited by 447 · see citing works
Dutt, S., Narla, A., Lin, K. I., Mullally, A., Abayasekara, N., Megerdichian, C., Wilson, F. H., Currie, T., Khanna‐Gupta, A., Berliner, N., et al. (2010) · Blood · doi:10.1182/blood-2010-07-295238 · Cited by 410 · see citing works
Self-citationHematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation
Scheller, M., Huelsken, J., Rosenbauer, F., Taketo, M. M., Birchmeier, W., Tenen, D. G., & Leutz, A. (2006) · Nature Immunology · doi:10.1038/ni1387 · Cited by 394 · see citing works
Albuquerque, C. M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.13.1549 · Cited by 392 · see citing works
Min, I. M., Pietramaggiori, G., Kim, F. S., Passegue, E. A., Stevenson, K. E., & Wagers, A. J. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.01.015 · Cited by 327 · see citing works
Canonical Wnt Signaling Regulates Hematopoiesis in a Dosage-Dependent Fashion
Luis, T. C., Naber, B. A. E., Roozen, P. P. C., Brugman, M. H., de Haas, E. F. E., Ghazvini, M., Fibbe, W. E., van Dongen, J. J. M., Fodde, R., & Staal, F. J. T. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.07.017 · Cited by 323 · see citing works
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 317 · see citing works
Gondek, L. P., Tiu, R. V., O’Keefe, C. L., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2007) · Blood · doi:10.1182/blood-2007-05-092304 · Cited by 315 · see citing works
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
Yeung, J., Esposito, M., Gandillet, A., Zeisig, B., Griessinger, E., Bonnet, D., & So, C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.032 · Cited by 264 · see citing works
Casein kinase 1: Complexity in the family
Cheong, J. K., & Virshup, D. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.12.004 · Cited by 256 · see citing works
Rena, G., Bain, J., Elliott, M., & Cohen, P. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400048 · Cited by 250 · see citing works
Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation
Trowbridge, J. J., Xenocostas, A., Moon, R. T., & Bhatia, M. (2005) · Nature Medicine · doi:10.1038/nm1339 · Cited by 247 · see citing works
Cancer vulnerabilities unveiled by genomic loss
Nijhawan, D., Zack, T., Ren, Y., Strickland, M., Lamothe, R., Schumacher, S., Tsherniak, A., Besche, H. C., Rosenbluh, J., Shehata, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.07.023 · Cited by 224 · see citing works
Luis, T. C., Ichii, M., Brugman, M. H., Kincade, P. W., & Staal, F. J. T. (2011) · Leukemia · doi:10.1038/leu.2011.387 · Cited by 209 · see citing works
Joslin, J. M., Fernald, A. A., Tennant, T. R., Davis, E. M., Kogan, S. C., Anastasi, J., Crispino, J. D., & Beau, M. M. L. (2007) · Blood · doi:10.1182/blood-2007-01-068809 · Cited by 208 · see citing works
CKIα ablation highlights a critical role for p53 in invasiveness control
Elyada, E., Pribluda, A., Goldstein, R. E., Morgenstern, Y., Brachya, G., Cojocaru, G., Snir-Alkalay, I., Burstain, I., Haffner‐Krausz, R., Jung, S., et al. (2011) · Nature · doi:10.1038/nature09673 · Cited by 199 · see citing works
Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival
Bidère, N., Ngo, V. N., Lee, J., Collins, C. T., Zheng, L., Wan, F., Davis, R. E., Lenz, G., Anderson, D. E., Arnoult, D., et al. (2008) · Nature · doi:10.1038/nature07613 · Cited by 174 · see citing works
Gene expression profiling of CD34+ cells in patients with the 5q− syndrome
Boultwood, J., Pellagatti, A., Cattan, H., Lawrie, C. H., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Fidler, C., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06833.x · Cited by 151 · see citing works
Miller, P., Al-Shahrour, F., Hartwell, K. A., Chu, L., Järås, M., Puram, R. V., Puissant, A., Callahan, K., Ashton, J., McConkey, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.004 · Cited by 144 · see citing works
Self-citationBoultwood, J., Pellagatti, A., McKenzie, A. N. J., & Wainscoat, J. S. (2010) · Blood · doi:10.1182/blood-2010-04-273771 · Cited by 120 · see citing works
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome
Kumar, M. S., Narla, A., Nonami, A., Mullally, A., Dimitrova, N., Ball, B. J., McAuley, J. R., Poveromo, L., Kutok, J. L., Galili, N., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324715 · Cited by 110 · see citing works
Self-citationTopography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
Jerez, A., Gondek, L. P., Jankowska, A. M., Makishima, H., Przychodzen, B. P., Tiu, R. V., O’Keefe, C. L., Mohamedali, A. M., Batista, D., Sekeres, M. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1824 · Cited by 110 · see citing works
The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS
Lane, S., Sykes, S. M., Al‐Shahrour, F., Shterental, S., Paktinat, M., Celso, C. L., Jesneck, J. L., Ebert, B. L., Williams, D. A., & Gilliland, D. G. (2010) · Blood · doi:10.1182/blood-2009-11-251728 · Cited by 99 · see citing works
Self-citationBaba, Y., Garrett, K. P., & Kincade, P. W. (2005) · Immunity · doi:10.1016/j.immuni.2005.10.009 · Cited by 96 · see citing works
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Järås, M., Miller, P. G., Chu, L. P., Puram, R. V., Fink, E. C., Schneider, R. K., Al-Shahrour, F., Peña, P., Breyfogle, L. J., Hartwell, K. A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131033 · Cited by 92 · see citing works
Self-citationHeinrichs, S., Kulkarni, R. V., Bueso‐Ramos, C. E., Levine, R. L., Loh, M. L., Li, C., Neuberg, D. S., Kornblau, S. M., Issa, J. J., Gilliland, D. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.82 · Cited by 89 · see citing works
Stoddart, A., Fernald, A. A., Wang, J., Davis, E. M., Karrison, T. G., Anastasi, J., & Beau, M. M. L. (2014) · Blood · doi:10.1182/blood-2013-07-517953 · Cited by 88 · see citing works
Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 85 · see citing works
Self-citationSinnberg, T. W., Menzel, M., Kaesler, S., Biedermann, T., Sauer, B., Nahnsen, S., Schwarz, M., Garbe, C., & Schittek, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0645 · Cited by 77 · see citing works
Haploinsufficiency of Apc leads to ineffective hematopoiesis
Wang, J., Fernald, A. A., Anastasi, J., Beau, M. M. L., & Qian, Z. (2010) · Blood · doi:10.1182/blood-2009-11-251835 · Cited by 71 · see citing works
Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome
Ebert, B. L. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.010 · Cited by 70 · see citing works
Self-citationKnockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice
Chen, T. H.-P., Kambal, A., Krysiak, K., Walshauser, M. A., Raju, G., Tibbitts, J. F., & Walter, M. J. (2010) · Blood · doi:10.1182/blood-2010-06-293167 · Cited by 54 · see citing works
Graubert, T. A., Payton, M. A., Shao, J., Walgren, R. A., Monahan, R. S., Frater, J. L., Walshauser, M. A., Martin, M. G., Kasai, Y., & Walter, M. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004583 · Cited by 50 · see citing works
Casein Kinase 1α Regulates an MDMX Intramolecular Interaction To Stimulate p53 Binding
Wu, S., Chen, L., Becker, A., Schönbrunn, E., & Chen, J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-12 · Cited by 48 · see citing works
Xu, J., Suzuki, M., Niwa, Y., Hiraga, J., Nagasaka, T., Ito, M., Nakamura, S., Tomita, A., Abe, A., Kiyoi, H., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06914.x · Cited by 44 · see citing works
Myelodysplastic Syndrome With Isolated del(5q)
(2018) · Elsevier eBooks · doi:10.1016/b978-0-323-39254-9.50116-1 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515 · see citing works
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works
Self-citationThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 676 · see citing works
Self-citationStructural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620 · see citing works
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · see citing works
“CK1a is essential for the survival of hematopoietic stem cells, and heterozygous deletion of its gene in del(5q) myelodysplastic syndrome provides a therapeutic window for eliminating the malignant stem cell clone (10).”
BackgroundSelf-citationCazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 496 · see citing works
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K., Peng, S., Aird, D. R., Bailey, S., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 455 · see citing works
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Beau, M. M. L. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.60 · Cited by 422 · see citing works
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 412 · see citing works
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 366 · see citing works
Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 298 · see citing works
Self-citationRps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 236 · see citing works
Self-citationThe novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213 · see citing works
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207 · see citing works
How Ribosomes Translate Cancer
Sulima, S. O., Hofman, I. J., Keersmaecker, K. D., & Dinman, J. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0550 · Cited by 174 · see citing works
A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity
Chung, K.-J., Chatzigeorgiou, A., Economopoulou, M., Garcia-Martin, R., Alexaki, V. I., Mitroulis, I., Nati, M., Gebler, J., Ziemssen, T., Goelz, S. E., et al. (2017) · Nature Immunology · doi:10.1038/ni.3728 · Cited by 175 · see citing works
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works
Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-03-657379 · Cited by 155 · see citing works
Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 155 · see citing works
Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 153 · see citing works
Self-citationCK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy
Cai, J., Li, R., Xu, X., Zhang, L., Lian, R., Fang, L., Huang, Y., Feng, X., Liu, X., Xu, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0065-8 · Cited by 145 · see citing works
Megakaryocyte and polyploidization
Mazzi, S., Lordier, L., Debili, N., Raslová, H., & Vainchenker, W. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.10.001 · Cited by 141 · see citing works
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 135 · see citing works
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Self-citationCrbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131 · see citing works
Self-citationCasein kinase 1α: biological mechanisms and theranostic potential
Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0236-z · Cited by 130 · see citing works
Pharmacological inhibition of the transcription factor PU.1 in leukemia
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92504 · Cited by 120 · see citing works
NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly
Niu, T., de Rosny, C., Chautard, S., Rey, A., Patoli, D., Groslambert, M., Cosson, C., Lagrange, B., Zhang, Z., Visvikis, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26142-w · Cited by 122 · see citing works
The molecular pathogenesis of the myelodysplastic syndromes
Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 116 · see citing works
Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141898 · Cited by 111 · see citing works
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 108 · see citing works
The phosphorylation switch that regulates ticking of the circadian clock
Narasimamurthy, R., & Virshup, D. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.006 · Cited by 105 · see citing works
Mercurio, A., Adriani, G., Catalano, A. A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170601074646 · Cited by 83 · see citing works
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 74 · see citing works
Emadali, A., Hoghoughi, N., Duley, S., Hajmirza, A., Verhoeyen, E., Cosset, F., Bertrand, P., Roumier, C., Roggy, A., Suchaud-Martin, C., et al. (2016) · Blood · doi:10.1182/blood-2015-09-671040 · Cited by 72 · see citing works
Genomic landscape of megakaryopoiesis and platelet function defects
Bianchi, E., Norfo, R., Pennucci, V., Zini, R., & Manfredini, R. (2016) · Blood · doi:10.1182/blood-2015-07-607952 · Cited by 70 · see citing works
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Janovská, P., Normant, E., Miskin, H. P., & Bryja, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239026 · Cited by 70 · see citing works
Clonal hematopoiesis in the inherited bone marrow failure syndromes
Tsai, F. D., & Lindsley, R. C. (2020) · Blood · doi:10.1182/blood.2019000990 · Cited by 66 · see citing works
Shi, Q., & Chen, L. (2017) · Journal of Immunology Research · doi:10.1155/2017/9130608 · Cited by 62 · see citing works
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57 · see citing works
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 55 · see citing works
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56 · see citing works
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52 · see citing works
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 50 · see citing works
Ribezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51 · see citing works
Self-citationA decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49 · see citing works
Self-citationMegakaryocyte polyploidization: role in platelet production
Vainchenker, W., & Raslová, H. (2019) · Platelets · doi:10.1080/09537104.2019.1667497 · Cited by 49 · see citing works
Qiu, J., Zhou, B., Thol, F. R., Zhou, Y., Chen, L., Shao, C., DeBoever, C., Hou, J., Li, H., Chaturvedi, A., et al. (2016) · RNA · doi:10.1261/rna.056101.116 · Cited by 48 · see citing works
Self-citationZini, R., Guglielmelli, P., Pietra, D., Rumi, E., Rossi, C., Rontauroli, S., Genovese, E., Fanelli, T., Calabresi, L., Bianchi, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0010-2 · Cited by 49 · see citing works
Mechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 45 · see citing works
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Hosono, N., Makishima, H., Mahfouz, R. Z., Przychodzen, B. P., Yoshida, K., Jerez, A., LaFramboise, T., Polprasert, C., Clemente, M. J., Shiraishi, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14130 · Cited by 45 · see citing works
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 44 · see citing works
Patil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 44 · see citing works
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis
Zhao, Z., Chen, C.-C., Rillahan, C. D., Shen, R., Kitzing, T. M., McNerney, M. E., Díaz-Flores, E., Zuber, J. A., Shannon, K., Beau, M. M. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3251 · Cited by 43 · see citing works
Molecular pathogenesis of myelodysplastic syndromes with deletion 5q
Lee, J.-H., List, A. F., & Sallman, D. A. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13207 · Cited by 43 · see citing works
Ferreira, M. S. V., Bergmann, C., Bodensiek, I., Peukert, K., Abert, J., Kramann, R., Kachel, P., Rath, B., Rütten, S., Knüchel, R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0234-9 · Cited by 42 · see citing works
Self-citationMolecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Negoro, E., Radivoyevitch, T., Polprasert, C., Ademà, V., Hosono, N., Makishima, H., Przychodzen, B. P., Hirsch, C., Clemente, M. J., Nazha, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.228 · Cited by 42 · see citing works
Self-citationTP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, M. V., Arber, D. A., & Hiwase, D. (2025) · American Journal of Hematology · doi:10.1002/ajh.27655 · Cited by 41 · see citing works
RECENT ADVANCES IN THE 5Q- SYNDROME
Pellagatti, A., & Boultwood, J. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2015.037 · Cited by 38 · see citing works
Manni, S., Carrino, M., & Piazza, F. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0529-5 · Cited by 39 · see citing works
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells
Liu, T., Krysiak, K., Shirai, C. L., Kim, S. P., Shao, J., Ndonwi, M., & Walter, M. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170470 · Cited by 36 · see citing works
CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation
Chang, C., Kuo, C.-J., Ito, T., Su, Y.-Y., Jiang, S., Chiu, M., Lin, Y., Nist, A., Mernberger, M., Stiewe, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702763114 · Cited by 36 · see citing works
Glycogen synthase kinase‐3 and alternative splicing
Liu, X., & Klein, P. S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1501 · Cited by 35 · see citing works
Role of reactive oxygen species in myelodysplastic syndromes
Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 33 · see citing works
Takai, A., Dang, H. T., Oishi, N., Khatib, S. A., Martin, S. P., Dominguez, D. A., Luo, J., Bagni, R., Wu, X., Powell, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3015 · Cited by 32 · see citing works
List, A. F., Sun, Z., Verma, A. K., Bennett, J. M., Komrokji, R. S., McGraw, K. L., Maciejewski, J. P., Altman, J. K., Cheema, P. S., Claxton, D. F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01691 · Cited by 32 · see citing works
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 29 · see citing works
Self-citationTIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease
Niederkorn, M., Agarwal, P., & Starczynowski, D. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.08.010 · Cited by 30 · see citing works
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29 · see citing works
Bereshchenko, O., Re, O. L., Nikulenkov, F., Flamini, S., Kotašková, J., Mazza, T., Pannérer, M.-M. L., Buschbeck, M., Giallongo, C., Palumbo, G. A., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0724-z · Cited by 30 · see citing works
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 30 · see citing works
Have we reached a molecular era in myelodysplastic syndromes?
Voso, M. T., & Gurnari, C. (2021) · Hematology · doi:10.1182/hematology.2021000276 · Cited by 27 · see citing works
Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts
Malcovati, L., & Cazzola, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14215 · Cited by 28 · see citing works
Primary Myelodysplastic Syndromes
Gangat, N., Patnaik, M. M., Begna, K. H., Kourelis, T., Al‐Kali, A., Elliott, M. A., Hogan, W. J., Letendre, L., Litzow, M. R., Knudson, R. A., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.08.022 · Cited by 27 · see citing works
Ganguly, B. B., Banerjee, D., & Agarwal, M. B. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.10.001 · Cited by 26 · see citing works
Chen, Z., Dhruv, H., Zhang, X., Rej, R. K., Bai, L., McEachern, D., Kirchhoff, P. D., Nagilla, R., Jolivette, L. J., Rice, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58431-z · Cited by 26 · see citing works
Targeting the Microenvironment in MDS: The Final Frontier
Teodorescu, P., Paşca, S., Dima, D. M., Tomuleasa, C., & Ghiaur, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01044 · Cited by 25 · see citing works
Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
Spinello, Z., Fregnani, A., Tubi, L. Q., Trentin, L., Piazza, F., & Manni, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073716 · Cited by 26 · see citing works
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 25 · see citing works
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 24 · see citing works
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
Bello, E., Pellagatti, A., Shaw, J. M., Mecucci, C., Kušec, R., Killick, S. B., Giagounidis, A. A. N., Raynaud, S., Calasanz, M. J., Fenaux, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13563 · Cited by 25 · see citing works
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26 · see citing works
Heuser, M., Meggendorfer, M., Cruz, M. M. A., Fabisch, J., Klesse, S., Köhler, L., Göhring, G., Ganster, C., Shirneshan, K., Gutermuth, A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.49 · Cited by 24 · see citing works
Smith, A., Kulasekararaj, A. G., Jiang, J., Mian, S. A., Mohamedali, A. M., Gäken, J. A., Ireland, R. M., Czepulkowski, B. H., Best, S., & Mufti, G. J. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00050-2 · Cited by 24 · see citing works
Suzuki, Y., Tomita, A., Nakamura, F., Iriyama, C., Shirahata‐Adachi, M., Shimada, K., Akashi, A., Ishikawa, Y., Kaneda, N., & Kiyoi, H. (2016) · Cancer Science · doi:10.1111/cas.12994 · Cited by 23 · see citing works
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 23 · see citing works
Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 24 · see citing works
β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)
Li, L., Sheng, Y., Li, W., Hu, C., Mittal, N., Tohyama, K., Seba, A., Zhao, Y., Ozer, H., Zhu, T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0202 · Cited by 20 · see citing works
Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_11 · Cited by 25 · see citing works
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias
Raundhal, M. R., Ghosh, S., Myers, S. A., Cuoco, M. S., Singer, M., Carr, S. A., Waikar, S. S., Bonventre, J. V., Ritz, J., Stone, R. M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00895-4 · Cited by 21 · see citing works
Biology of Erythropoiesis, Erythroid Differentiation, and Maturation
Papayannopoulou, T., & Migliaccio, A. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00026-3 · Cited by 21 · see citing works
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21 · see citing works
The Coming of Age of Preclinical Models of MDS
Liu, W., Teodorescu, P., Halene, S., & Ghiaur, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.815037 · Cited by 20 · see citing works
Lee, E.-J., & Zeidan, A. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1016905 · Cited by 19 · see citing works
Stoner, S. A., Yan, M., Liu, K. T. H., Arimoto, K., Shima, T., Wang, H., Johnson, D. T., Bejar, R. L., Jamieson, C. H. M., Guan, K., et al. (2019) · Blood · doi:10.1182/blood.2019000170 · Cited by 19 · see citing works
Self-citationPathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
Ademà, V., Palomo, L., Walter, W., Mallo, M., Hütter, S., Framboise, T. L., Arenillas, L., Meggendorfer, M., Radivoyevitch, T., Xicoy, B., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104059 · Cited by 18 · see citing works
Self-citationTargeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll, P. S., Yoshizato, T., Hellström‐Lindberg, E., Fioretos, T., Ebert, B. L., & Jacobsen, S. E. W. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13535 · Cited by 15 · see citing works
Self-citationGenetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nardi, V., & Hasserjian, R. P. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.004 · Cited by 18 · see citing works
Rasmussen, B. E. H., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H. G., Dybedal, I., Grønbæk, K., Ejerblad, E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01537-w · Cited by 17 · see citing works
The Genetic Architecture of Murine Glutathione Transferases
Lu, L., Pandey, A. K., Houseal, M. T., & Mulligan, M. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148230 · Cited by 17 · see citing works
- Authors
- Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., Bejar, R., Solé, F., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Universitat Autònoma de Barcelona (ES)
- University of California San Diego (US)
- Broad Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 26
- Issue
- 4
- Pages
- 509-520
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4199102
- OpenAlex
- W2081870738
- Cited by
- 188
- References
- 52
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 5 · 2022: 16 · 2021: 18 · 2020: 16 · 2019: 13 · 2018: 20 · 2017: 24 · 2016: 22 · 2015: 19 · 2014: 1
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Harvard Stem Cell Institute
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Cancer Institute (P30CA023100, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK091360)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- CSNK1A1, del(5q) myelodysplastic syndrome, tumor suppressor, haploinsufficiency, hematopoietic stem cells, competitive repopulation, conditional knockout mouse model, somatic mutations, therapeutic target
- MeSH terms
- Aged, Animals, Base Sequence, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Flow Cytometry, Humans, Male, Mutation, Myelodysplastic Syndromes, Polymerase Chain Reaction, DNA Primers, Casein Kinase I, Mice, Young Adult, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
